Top 12 Prostate cancer treatment startups in USA
Jan 10, 2026
|
Like
18
1
Funding: $460.5M
Poseida Therapeutics develops differentiated allogeneic cell therapies and genetic medicines using our proprietary genetic engineering platforms. The company develops the piggyBac non-viral DNA delivery system (which enables introduction of large genetic data into the genome) and the Cas-CLOVER site-specific gene editing system (which can be used for precise site-specific deletions, insertions and knockouts in various cell types). Using this platform, the company creates CAR-T therapies with high levels of desired TSCM (stem cell-derived memory T cells) for the treatment of a range of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer. Poseida was acquired by Roche in early 2025.
Poseida Therapeutics develops differentiated allogeneic cell therapies and genetic medicines using our proprietary genetic engineering platforms. The company develops the piggyBac non-viral DNA delivery system (which enables introduction of large genetic data into the genome) and the Cas-CLOVER site-specific gene editing system (which can be used for precise site-specific deletions, insertions and knockouts in various cell types). Using this platform, the company creates CAR-T therapies with high levels of desired TSCM (stem cell-derived memory T cells) for the treatment of a range of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer. Poseida was acquired by Roche in early 2025.
2
Funding: $220M
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
3
Funding: $208.3M
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
4
Funding: $205M
Flare Therapeutics develops personalized drugs based on transcription factors - DNA-binding proteins that can activate or repress DNA transcription and, therefore, control gene expression. As drug targets, TFs differ from many other classes of targets in that they determine the identity of cells and tissues, controlling which genes are expressed and which are not. The integrated FlareTx platform uses two complementary strategies to identify potential ligand-binding sites within transcription factors: site mapping and chemoproteomics. Flare Therapeutics' initial focus is precision oncology, with leading programs in advanced urothelial cancer and prostate cancer. Their small molecules are designed to restore transcriptional control disrupted by cancer.
Flare Therapeutics develops personalized drugs based on transcription factors - DNA-binding proteins that can activate or repress DNA transcription and, therefore, control gene expression. As drug targets, TFs differ from many other classes of targets in that they determine the identity of cells and tissues, controlling which genes are expressed and which are not. The integrated FlareTx platform uses two complementary strategies to identify potential ligand-binding sites within transcription factors: site mapping and chemoproteomics. Flare Therapeutics' initial focus is precision oncology, with leading programs in advanced urothelial cancer and prostate cancer. Their small molecules are designed to restore transcriptional control disrupted by cancer.
5
Funding: $130M
Convergent Therapeutics develops radiopharmaceuticals for the treatment of prostate cancer. These are radioantibodies that deliver alpha-emitting agents, which carry the radioactive payload directly to the cancer cells, making radiation therapy more targeted and effective. The short-acting nature of these alpha-emitting agents minimizes radiation exposure to healthy adjacent cells and tissue. Each radioantibody is created through careful selection of an antibody with high affinity for a specific cancer target. The company's flagship drug, CONV01-α, is a radioantibody labeled with actinium-225, with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients.
Convergent Therapeutics develops radiopharmaceuticals for the treatment of prostate cancer. These are radioantibodies that deliver alpha-emitting agents, which carry the radioactive payload directly to the cancer cells, making radiation therapy more targeted and effective. The short-acting nature of these alpha-emitting agents minimizes radiation exposure to healthy adjacent cells and tissue. Each radioantibody is created through careful selection of an antibody with high affinity for a specific cancer target. The company's flagship drug, CONV01-α, is a radioantibody labeled with actinium-225, with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients.
6
Funding: $110M
Artera is developing an AI system for prostate cancer diagnostics. It analyzes patient biopsy images and accurately predicts the likelihood of benefit from specific treatments, allowing doctors to make treatment decisions with greater confidence. The system is based on a multimodal AI model trained on digital pathological images and text-based clinical data. In addition to images, it analyzes numerous patient characteristics and performs tasks that traditional methods cannot perform independently. Test results are generated without the use of tissue and are available for review within 2-3 days of receiving the patient's sample.
Artera is developing an AI system for prostate cancer diagnostics. It analyzes patient biopsy images and accurately predicts the likelihood of benefit from specific treatments, allowing doctors to make treatment decisions with greater confidence. The system is based on a multimodal AI model trained on digital pathological images and text-based clinical data. In addition to images, it analyzes numerous patient characteristics and performs tasks that traditional methods cannot perform independently. Test results are generated without the use of tissue and are available for review within 2-3 days of receiving the patient's sample.
7
Funding: $43M
Ezra develops technology for detecting cancer early using MRI & AI. Starting with prostate cancer.
Ezra develops technology for detecting cancer early using MRI & AI. Starting with prostate cancer.
8
Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
9
Funding: $27.8M
Talus Bio is a drug discovery biotech startup that develops drugs targeting undruggable transcription factors using AI.
Talus Bio is a drug discovery biotech startup that develops drugs targeting undruggable transcription factors using AI.
11
Dendreon was a biotechnology company produces immunotherapy for prostate cancer. Its cancer vaccine uses a patient’s own immune cells, which are collected, processed and infused back into the individual through an intravenous infusion that is completed in three cycles.
12
Funding: $1.5M
Bot Image develops software ProstatID - for post processing MRI using cloud based computing, physician workstation integration, and AI image interpretation to provide highly accurate prostate cancer diagnostics.
Bot Image develops software ProstatID - for post processing MRI using cloud based computing, physician workstation integration, and AI image interpretation to provide highly accurate prostate cancer diagnostics.
★
See also:
